BackAcumen Pharmaceuticals Overview

Acumen Pharmaceuticals Current Assets

Track Acumen Pharmaceuticals's current assets ($130M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$133.09M
14.10% YoYΔ $-21.85M vs prior year quarter

Peer average

Loading

Acumen Pharmaceuticals Current Assets History

Loading

Acumen Pharmaceuticals vs. peers: Current Assets Comparison

Loading

Acumen Pharmaceuticals Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Acumen Pharmaceuticals (ABOS) FAQ

Acumen Pharmaceuticals's current assets stands at $130M as of March 2026. That compares with $150M in the prior-year period — down 14.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Acumen Pharmaceuticals reported $130M in current assets versus $150M a year earlier — a 14.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $150M in the prior-year period — down 14.1% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Acumen Pharmaceuticals's current assets evolved across reporting periods, while the comparison chart places ABOS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. Acumen Pharmaceuticals's reading of $130M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.